Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

PRIMARY OBJECTIVES: I. Evaluate the toxicity of the use of vorinostat and bortezomib as maintenance therapy after autologous transplant. SECONDARY OBJECTIVES: I. Evaluate the median time to disease progression. II. Evaluate survival. OUTLINE: Patients receive bortezomib intravenously (IV) on days 2 and 5 and vorinostat orally (PO) once daily (QD) on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.